uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q16.396 | Q16 | What Small molecule therapies have been approved by the FDA to treat Combined hyperlipidemia? | There are no drug Small molecule therapies approved to treat Combined hyperlipidemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "combined hyperlipidemia" OR LOWER(mesh_heading) = "combined hyperlipidemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.583 | Q16 | What Small molecule therapies have been approved by the FDA to treat Parathyroid Gland Carcinoma? | Cinacalcet Hydrochloride is the only Small molecule therapy approved by the FDA to treat Parathyroid Gland Carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "parathyroid gland carcinoma" OR LOWER(mesh_heading) = "parathyroid gland carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149011', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Neoplasms', 'efo_term': 'Parathyroid Gland Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1149016', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Neoplasms', 'efo_term': 'Parathyroid Gland Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1149021', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Neoplasms', 'efo_term': 'Parathyroid Gland Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1149026', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Neoplasms', 'efo_term': 'Parathyroid Gland Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1149031', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Neoplasms', 'efo_term': 'Parathyroid Gland Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1149036', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Neoplasms', 'efo_term': 'Parathyroid Gland Carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.25 | Q16 | What Protein therapies have been approved by the FDA to treat B-Cell Prolymphocytic Leukemia? | There are no drug Protein therapies approved to treat B-Cell Prolymphocytic Leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "b-cell prolymphocytic leukemia" OR LOWER(mesh_heading) = "b-cell prolymphocytic leukemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.212 | Q16 | What Protein therapies have been approved by the FDA to treat malnutrition? | There are no drug Protein therapies approved to treat malnutrition. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "malnutrition" OR LOWER(mesh_heading) = "malnutrition") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1354 | Q16 | What Small molecule therapies have been approved by the FDA to treat myocarditis? | There are 2 Small molecule therapy drugs that are approved to treat myocarditis which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myocarditis" OR LOWER(mesh_heading) = "myocarditis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217661', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_217869', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_218077', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_218285', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_218493', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_218701', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_218909', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_219117', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_219325', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_219533', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_219741', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_219949', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_220157', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_220365', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_220573', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_220781', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_226357', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_226642', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_226927', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_227212', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_227497', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_227782', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_228067', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_228352', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_228637', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_228922', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_229207', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_229492', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_229777', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_230062', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_230347', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_230632', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_230917', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_231202', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_231487', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_231772', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_232057', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}, {'UUID': 'DrugTargetsIndication121923_text_232342', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.145 | Q16 | What Protein therapies have been approved by the FDA to treat diabetic retinopathy? | There are no drug Protein therapies approved to treat diabetic retinopathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "diabetic retinopathy" OR LOWER(mesh_heading) = "diabetic retinopathy") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.540 | Q16 | What Small molecule therapies have been approved by the FDA to treat Mantle cell lymphoma? | There are 6 Small molecule therapy drugs that are approved to treat Mantle cell lymphoma which are as follows: Bortezomib, Acalabrutinib, Ibrutinib, Acalabrutinib Maleate, Zanubrutinib, and Lenalidomide. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mantle cell lymphoma" OR LOWER(mesh_heading) = "mantle cell lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_341847', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_341947', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_342047', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_342147', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_342247', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_342347', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_342447', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_342547', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_342647', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000008018', 'approvedSymbol': 'PSMB1', 'approvedName': 'proteasome 20S subunit beta 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_342747', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000008018', 'approvedSymbol': 'PSMB1', 'approvedName': 'proteasome 20S subunit beta 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_342847', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000008018', 'approvedSymbol': 'PSMB1', 'approvedName': 'proteasome 20S subunit beta 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_342947', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000008018', 'approvedSymbol': 'PSMB1', 'approvedName': 'proteasome 20S subunit beta 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_343047', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100804', 'approvedSymbol': 'PSMB5', 'approvedName': 'proteasome 20S subunit beta 5', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_343147', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100804', 'approvedSymbol': 'PSMB5', 'approvedName': 'proteasome 20S subunit beta 5', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_343247', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100804', 'approvedSymbol': 'PSMB5', 'approvedName': 'proteasome 20S subunit beta 5', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_343347', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100804', 'approvedSymbol': 'PSMB5', 'approvedName': 'proteasome 20S subunit beta 5', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_343447', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000204264', 'approvedSymbol': 'PSMB8', 'approvedName': 'proteasome 20S subunit beta 8', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_343547', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000204264', 'approvedSymbol': 'PSMB8', 'approvedName': 'proteasome 20S subunit beta 8', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_343647', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000204264', 'approvedSymbol': 'PSMB8', 'approvedName': 'proteasome 20S subunit beta 8', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_343747', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000204264', 'approvedSymbol': 'PSMB8', 'approvedName': 'proteasome 20S subunit beta 8', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_343847', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000240065', 'approvedSymbol': 'PSMB9', 'approvedName': 'proteasome 20S subunit beta 9', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_343947', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000240065', 'approvedSymbol': 'PSMB9', 'approvedName': 'proteasome 20S subunit beta 9', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_344047', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000240065', 'approvedSymbol': 'PSMB9', 'approvedName': 'proteasome 20S subunit beta 9', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_344147', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000240065', 'approvedSymbol': 'PSMB9', 'approvedName': 'proteasome 20S subunit beta 9', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_344247', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142507', 'approvedSymbol': 'PSMB6', 'approvedName': 'proteasome 20S subunit beta 6', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_344347', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142507', 'approvedSymbol': 'PSMB6', 'approvedName': 'proteasome 20S subunit beta 6', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_344447', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142507', 'approvedSymbol': 'PSMB6', 'approvedName': 'proteasome 20S subunit beta 6', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_344547', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142507', 'approvedSymbol': 'PSMB6', 'approvedName': 'proteasome 20S subunit beta 6', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_344647', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115233', 'approvedSymbol': 'PSMD14', 'approvedName': 'proteasome 26S subunit, non-ATPase 14', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_344747', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115233', 'approvedSymbol': 'PSMD14', 'approvedName': 'proteasome 26S subunit, non-ATPase 14', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_344847', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115233', 'approvedSymbol': 'PSMD14', 'approvedName': 'proteasome 26S subunit, non-ATPase 14', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_344947', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115233', 'approvedSymbol': 'PSMD14', 'approvedName': 'proteasome 26S subunit, non-ATPase 14', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_345047', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129084', 'approvedSymbol': 'PSMA1', 'approvedName': 'proteasome 20S subunit alpha 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_345147', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129084', 'approvedSymbol': 'PSMA1', 'approvedName': 'proteasome 20S subunit alpha 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_345247', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129084', 'approvedSymbol': 'PSMA1', 'approvedName': 'proteasome 20S subunit alpha 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_345347', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129084', 'approvedSymbol': 'PSMA1', 'approvedName': 'proteasome 20S subunit alpha 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_345447', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106588', 'approvedSymbol': 'PSMA2', 'approvedName': 'proteasome 20S subunit alpha 2', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_345547', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106588', 'approvedSymbol': 'PSMA2', 'approvedName': 'proteasome 20S subunit alpha 2', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_345647', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106588', 'approvedSymbol': 'PSMA2', 'approvedName': 'proteasome 20S subunit alpha 2', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_345747', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106588', 'approvedSymbol': 'PSMA2', 'approvedName': 'proteasome 20S subunit alpha 2', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_345847', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100567', 'approvedSymbol': 'PSMA3', 'approvedName': 'proteasome 20S subunit alpha 3', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_345947', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100567', 'approvedSymbol': 'PSMA3', 'approvedName': 'proteasome 20S subunit alpha 3', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_346047', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100567', 'approvedSymbol': 'PSMA3', 'approvedName': 'proteasome 20S subunit alpha 3', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_346147', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100567', 'approvedSymbol': 'PSMA3', 'approvedName': 'proteasome 20S subunit alpha 3', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_346247', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000041357', 'approvedSymbol': 'PSMA4', 'approvedName': 'proteasome 20S subunit alpha 4', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_346347', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000041357', 'approvedSymbol': 'PSMA4', 'approvedName': 'proteasome 20S subunit alpha 4', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_346447', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000041357', 'approvedSymbol': 'PSMA4', 'approvedName': 'proteasome 20S subunit alpha 4', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_346547', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000041357', 'approvedSymbol': 'PSMA4', 'approvedName': 'proteasome 20S subunit alpha 4', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_346647', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143106', 'approvedSymbol': 'PSMA5', 'approvedName': 'proteasome 20S subunit alpha 5', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_346747', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143106', 'approvedSymbol': 'PSMA5', 'approvedName': 'proteasome 20S subunit alpha 5', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_346847', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143106', 'approvedSymbol': 'PSMA5', 'approvedName': 'proteasome 20S subunit alpha 5', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_346947', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143106', 'approvedSymbol': 'PSMA5', 'approvedName': 'proteasome 20S subunit alpha 5', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_347047', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100902', 'approvedSymbol': 'PSMA6', 'approvedName': 'proteasome 20S subunit alpha 6', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_347147', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100902', 'approvedSymbol': 'PSMA6', 'approvedName': 'proteasome 20S subunit alpha 6', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_347247', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100902', 'approvedSymbol': 'PSMA6', 'approvedName': 'proteasome 20S subunit alpha 6', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_347347', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100902', 'approvedSymbol': 'PSMA6', 'approvedName': 'proteasome 20S subunit alpha 6', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_347447', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101182', 'approvedSymbol': 'PSMA7', 'approvedName': 'proteasome 20S subunit alpha 7', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_347547', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101182', 'approvedSymbol': 'PSMA7', 'approvedName': 'proteasome 20S subunit alpha 7', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_347647', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101182', 'approvedSymbol': 'PSMA7', 'approvedName': 'proteasome 20S subunit alpha 7', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_347747', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101182', 'approvedSymbol': 'PSMA7', 'approvedName': 'proteasome 20S subunit alpha 7', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_347847', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154611', 'approvedSymbol': 'PSMA8', 'approvedName': 'proteasome 20S subunit alpha 8', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_347947', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154611', 'approvedSymbol': 'PSMA8', 'approvedName': 'proteasome 20S subunit alpha 8', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_348047', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154611', 'approvedSymbol': 'PSMA8', 'approvedName': 'proteasome 20S subunit alpha 8', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_348147', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154611', 'approvedSymbol': 'PSMA8', 'approvedName': 'proteasome 20S subunit alpha 8', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_348247', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000205220', 'approvedSymbol': 'PSMB10', 'approvedName': 'proteasome 20S subunit beta 10', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_348347', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000205220', 'approvedSymbol': 'PSMB10', 'approvedName': 'proteasome 20S subunit beta 10', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_348447', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000205220', 'approvedSymbol': 'PSMB10', 'approvedName': 'proteasome 20S subunit beta 10', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_348547', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000205220', 'approvedSymbol': 'PSMB10', 'approvedName': 'proteasome 20S subunit beta 10', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_348647', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000222028', 'approvedSymbol': 'PSMB11', 'approvedName': 'proteasome subunit beta 11', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_348747', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000222028', 'approvedSymbol': 'PSMB11', 'approvedName': 'proteasome subunit beta 11', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_348847', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000222028', 'approvedSymbol': 'PSMB11', 'approvedName': 'proteasome subunit beta 11', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_348947', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000222028', 'approvedSymbol': 'PSMB11', 'approvedName': 'proteasome subunit beta 11', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_349047', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000277791', 'approvedSymbol': 'PSMB3', 'approvedName': 'proteasome 20S subunit beta 3', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_349147', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000277791', 'approvedSymbol': 'PSMB3', 'approvedName': 'proteasome 20S subunit beta 3', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_349247', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000277791', 'approvedSymbol': 'PSMB3', 'approvedName': 'proteasome 20S subunit beta 3', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_349347', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000277791', 'approvedSymbol': 'PSMB3', 'approvedName': 'proteasome 20S subunit beta 3', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_349447', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159377', 'approvedSymbol': 'PSMB4', 'approvedName': 'proteasome 20S subunit beta 4', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_349547', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159377', 'approvedSymbol': 'PSMB4', 'approvedName': 'proteasome 20S subunit beta 4', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_349647', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159377', 'approvedSymbol': 'PSMB4', 'approvedName': 'proteasome 20S subunit beta 4', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_349747', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159377', 'approvedSymbol': 'PSMB4', 'approvedName': 'proteasome 20S subunit beta 4', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_349847', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136930', 'approvedSymbol': 'PSMB7', 'approvedName': 'proteasome 20S subunit beta 7', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_349947', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136930', 'approvedSymbol': 'PSMB7', 'approvedName': 'proteasome 20S subunit beta 7', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_350047', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136930', 'approvedSymbol': 'PSMB7', 'approvedName': 'proteasome 20S subunit beta 7', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_350147', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000136930', 'approvedSymbol': 'PSMB7', 'approvedName': 'proteasome 20S subunit beta 7', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_350247', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000130706', 'approvedSymbol': 'ADRM1', 'approvedName': 'ADRM1 26S proteasome ubiquitin receptor', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_350347', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000130706', 'approvedSymbol': 'ADRM1', 'approvedName': 'ADRM1 26S proteasome ubiquitin receptor', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_350447', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000130706', 'approvedSymbol': 'ADRM1', 'approvedName': 'ADRM1 26S proteasome ubiquitin receptor', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_350547', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000130706', 'approvedSymbol': 'ADRM1', 'approvedName': 'ADRM1 26S proteasome ubiquitin receptor', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_350647', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000161057', 'approvedSymbol': 'PSMC2', 'approvedName': 'proteasome 26S subunit, ATPase 2', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_350747', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000161057', 'approvedSymbol': 'PSMC2', 'approvedName': 'proteasome 26S subunit, ATPase 2', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_350847', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000161057', 'approvedSymbol': 'PSMC2', 'approvedName': 'proteasome 26S subunit, ATPase 2', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_350947', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000161057', 'approvedSymbol': 'PSMC2', 'approvedName': 'proteasome 26S subunit, ATPase 2', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_351047', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100764', 'approvedSymbol': 'PSMC1', 'approvedName': 'proteasome 26S subunit, ATPase 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_351147', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100764', 'approvedSymbol': 'PSMC1', 'approvedName': 'proteasome 26S subunit, ATPase 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_351247', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100764', 'approvedSymbol': 'PSMC1', 'approvedName': 'proteasome 26S subunit, ATPase 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_351347', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100764', 'approvedSymbol': 'PSMC1', 'approvedName': 'proteasome 26S subunit, ATPase 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_351447', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000013275', 'approvedSymbol': 'PSMC4', 'approvedName': 'proteasome 26S subunit, ATPase 4', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_351547', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000013275', 'approvedSymbol': 'PSMC4', 'approvedName': 'proteasome 26S subunit, ATPase 4', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_351647', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000013275', 'approvedSymbol': 'PSMC4', 'approvedName': 'proteasome 26S subunit, ATPase 4', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_351747', 'drugName': 'Bortezomib', 'tradeNames_list': "['Velcade']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000013275', 'approvedSymbol': 'PSMC4', 'approvedName': 'proteasome 26S subunit, ATPase 4', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.819 | Q16 | What Small molecule therapies have been approved by the FDA to treat biliary atresia? | There are no drug Small molecule therapies approved to treat biliary atresia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "biliary atresia" OR LOWER(mesh_heading) = "biliary atresia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1209 | Q16 | What Small molecule therapies have been approved by the FDA to treat intestinal neoplasm? | There are no drug Small molecule therapies approved to treat intestinal neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "intestinal neoplasm" OR LOWER(mesh_heading) = "intestinal neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1176 | Q16 | What Small molecule therapies have been approved by the FDA to treat hypotrichosis? | Bimatoprost is the only Small molecule therapy approved by the FDA to treat hypotrichosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypotrichosis" OR LOWER(mesh_heading) = "hypotrichosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149132', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149133', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149141', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149142', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149150', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149151', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149159', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149160', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149168', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149169', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149177', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149178', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149186', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149187', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149195', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149196', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149204', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149205', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149213', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149214', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149222', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149223', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149231', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149232', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149240', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149241', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149249', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149250', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149258', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149259', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149267', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149268', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149276', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149277', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149285', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149286', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149294', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149295', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149303', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149304', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149312', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149313', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149321', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149322', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149330', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149331', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149339', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149340', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149348', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149349', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149357', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149358', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149366', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149367', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149375', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149376', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149384', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149385', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149393', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149394', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}, {'UUID': 'DrugTargetsIndication121923_text_1149402', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis'}, {'UUID': 'DrugTargetsIndication121923_text_1149403', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000122420', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypotrichosis', 'efo_term': 'hypotrichosis simplex'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.86 | Q16 | What Protein therapies have been approved by the FDA to treat adenoma? | There are no drug Protein therapies approved to treat adenoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "adenoma" OR LOWER(mesh_heading) = "adenoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1586 | Q16 | What Small molecule therapies have been approved by the FDA to treat rhabdomyosarcoma? | There are no drug Small molecule therapies approved to treat rhabdomyosarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "rhabdomyosarcoma" OR LOWER(mesh_heading) = "rhabdomyosarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.274 | Q16 | What Protein therapies have been approved by the FDA to treat prostate cancer? | There are 3 Protein therapy drugs that are approved to treat prostate cancer which are as follows: Leuprolide Acetate, Histrelin Acetate, and Leuprolide Mesylate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "prostate cancer" OR LOWER(mesh_heading) = "prostate cancer") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097007', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097029', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097051', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097073', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097095', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097117', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097121', 'drugName': 'Histrelin Acetate', 'tradeNames_list': "['Supprelin', 'Supprelin la', 'Vantas']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097125', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097129', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097133', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097137', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097141', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097145', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097149', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097153', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097157', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097161', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097306', 'drugName': 'Leuprolide Mesylate', 'tradeNames_list': "['Camcevi kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097307', 'drugName': 'Leuprolide Mesylate', 'tradeNames_list': "['Camcevi kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1097308', 'drugName': 'Leuprolide Mesylate', 'tradeNames_list': "['Camcevi kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1137 | Q16 | What Small molecule therapies have been approved by the FDA to treat hemophilia A? | Tranexamic Acid is the only Small molecule therapy approved by the FDA to treat hemophilia A. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hemophilia a" OR LOWER(mesh_heading) = "hemophilia a") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993329', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A'}, {'UUID': 'DrugTargetsIndication121923_text_993387', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A'}, {'UUID': 'DrugTargetsIndication121923_text_993445', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A'}, {'UUID': 'DrugTargetsIndication121923_text_993503', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A'}, {'UUID': 'DrugTargetsIndication121923_text_993561', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A'}, {'UUID': 'DrugTargetsIndication121923_text_993619', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A'}, {'UUID': 'DrugTargetsIndication121923_text_993677', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A'}, {'UUID': 'DrugTargetsIndication121923_text_993735', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122194', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1050 | Q16 | What Small molecule therapies have been approved by the FDA to treat eye allergy? | Alcaftadine is the only Small molecule therapy approved by the FDA to treat eye allergy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "eye allergy" OR LOWER(mesh_heading) = "eye allergy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455860', 'drugName': 'Alcaftadine', 'tradeNames_list': "['Lastacaft']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Manifestations', 'efo_term': 'eye allergy'}, {'UUID': 'DrugTargetsIndication121923_text_455862', 'drugName': 'Alcaftadine', 'tradeNames_list': "['Lastacaft']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Manifestations', 'efo_term': 'eye allergy'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1561 | Q16 | What Small molecule therapies have been approved by the FDA to treat reactive arthritis? | There are no drug Small molecule therapies approved to treat reactive arthritis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "reactive arthritis" OR LOWER(mesh_heading) = "reactive arthritis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1588 | Q16 | What Small molecule therapies have been approved by the FDA to treat rheumatic heart disease? | There are no drug Small molecule therapies approved to treat rheumatic heart disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "rheumatic heart disease" OR LOWER(mesh_heading) = "rheumatic heart disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.634 | Q16 | What Small molecule therapies have been approved by the FDA to treat Status Asthmaticus? | There are no drug Small molecule therapies approved to treat Status Asthmaticus. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "status asthmaticus" OR LOWER(mesh_heading) = "status asthmaticus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1400 | Q16 | What Small molecule therapies have been approved by the FDA to treat ophthalmic herpes zoster? | There are 2 Small molecule therapy drugs that are approved to treat ophthalmic herpes zoster which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ophthalmic herpes zoster" OR LOWER(mesh_heading) = "ophthalmic herpes zoster") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217655', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_217863', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_218071', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_218279', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_218487', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_218695', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_218903', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_219111', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_219319', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_219527', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_219735', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_219943', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_220151', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_220359', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_220567', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_220775', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_226350', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_226635', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_226920', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_227205', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_227490', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_227775', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_228060', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_228345', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_228630', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_228915', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_229200', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_229485', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_229770', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_230055', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_230340', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_230625', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_230910', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_231195', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_231480', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_231765', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_232050', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}, {'UUID': 'DrugTargetsIndication121923_text_232335', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Zoster Ophthalmicus', 'efo_term': 'ophthalmic herpes zoster'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1646 | Q16 | What Small molecule therapies have been approved by the FDA to treat spinal muscular atrophy? | Risdiplam is the only Small molecule therapy approved by the FDA to treat spinal muscular atrophy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "spinal muscular atrophy" OR LOWER(mesh_heading) = "spinal muscular atrophy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072735', 'drugName': 'Risdiplam', 'tradeNames_list': "['Evrysdi']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000205571', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy'}, {'UUID': 'DrugTargetsIndication121923_text_1072737', 'drugName': 'Risdiplam', 'tradeNames_list': "['Evrysdi']", 'drugType': 'Small molecule', 'actionType': 'positive modulator', 'target': 'ENSG00000205571', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1612 | Q16 | What Small molecule therapies have been approved by the FDA to treat secondary progressive multiple sclerosis? | There are no drug Small molecule therapies approved to treat secondary progressive multiple sclerosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "secondary progressive multiple sclerosis" OR LOWER(mesh_heading) = "secondary progressive multiple sclerosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1667 | Q16 | What Small molecule therapies have been approved by the FDA to treat substance abuse? | There are 2 Small molecule therapy drugs that are approved to treat substance abuse which are as follows: Buprenorphine and Oxycodone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "substance abuse" OR LOWER(mesh_heading) = "substance abuse") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_764059', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764087', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764115', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764143', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764171', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764199', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764227', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764255', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764283', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764311', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764339', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764367', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764395', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764423', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764451', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764479', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764507', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764535', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764563', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764591', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764619', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764647', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764675', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764703', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764731', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764759', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764787', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764815', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764843', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764871', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764899', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764927', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764955', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_764983', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765011', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765039', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765067', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765095', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765123', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765151', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765179', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765207', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765235', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765263', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765291', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765319', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765347', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765375', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765403', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765431', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765459', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765487', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765515', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765543', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765571', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765599', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765627', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765655', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765683', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765711', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765739', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765767', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765795', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765823', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765851', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765879', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765907', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765935', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765963', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_765991', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766019', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766047', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766075', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766103', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766131', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766159', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766187', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766215', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766243', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766271', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766299', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766327', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766355', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766383', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766411', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766439', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766467', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766495', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766523', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_766551', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_767960', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_767993', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_768026', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_768059', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_768092', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_768125', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_768158', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_768191', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_768224', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}, {'UUID': 'DrugTargetsIndication121923_text_768257', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.509 | Q16 | What Small molecule therapies have been approved by the FDA to treat IGA glomerulonephritis? | There are no drug Small molecule therapies approved to treat IGA glomerulonephritis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "iga glomerulonephritis" OR LOWER(mesh_heading) = "iga glomerulonephritis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.275 | Q16 | What Protein therapies have been approved by the FDA to treat prostate carcinoma? | There are 3 Protein therapy drugs that are approved to treat prostate carcinoma which are as follows: Leuprolide Acetate, Degarelix Acetate, and Triptorelin Pamoate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "prostate carcinoma" OR LOWER(mesh_heading) = "prostate carcinoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097004', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097026', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097048', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097070', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097092', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097114', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097124', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097128', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097132', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097136', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097140', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097144', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097148', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097152', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097156', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097160', 'drugName': 'Degarelix Acetate', 'tradeNames_list': "['Firmagon']", 'drugType': 'Protein', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097286', 'drugName': 'Triptorelin Pamoate', 'tradeNames_list': "['Trelstar', 'Triptodur kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1097293', 'drugName': 'Triptorelin Pamoate', 'tradeNames_list': "['Trelstar', 'Triptodur kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.976 | Q16 | What Small molecule therapies have been approved by the FDA to treat deep vein thrombosis? | There are 4 Small molecule therapy drugs that are approved to treat deep vein thrombosis which are as follows: Rivaroxaban, Edoxaban Tosylate, Apixaban, and Dabigatran Etexilate Mesylate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "deep vein thrombosis" OR LOWER(mesh_heading) = "deep vein thrombosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_708683', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708718', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708753', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708788', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708823', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708858', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708893', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708928', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708963', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_708998', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709033', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709068', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709103', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709138', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709173', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709208', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709243', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709278', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709313', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709348', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709383', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709418', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709453', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709488', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709523', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709558', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709593', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709628', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709663', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709698', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709733', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709768', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709803', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709838', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709873', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709908', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709943', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_709978', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710013', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710048', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710083', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710118', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710153', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710188', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710223', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710258', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710293', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710301', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710308', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710315', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710322', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710329', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710336', 'drugName': 'Edoxaban Tosylate', 'tradeNames_list': "['Savaysa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710364', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710393', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710422', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710451', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710480', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710509', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710538', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710567', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710596', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710625', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710654', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710683', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710712', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710741', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_710770', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092370', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092375', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092380', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092385', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092390', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092395', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092400', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092405', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092410', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092415', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092420', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092425', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092430', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092435', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092440', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092445', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092450', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092455', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092460', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092465', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092470', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092475', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092480', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092485', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092490', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092495', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092500', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092505', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092510', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092515', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092520', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}, {'UUID': 'DrugTargetsIndication121923_text_1092525', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1293 | Q16 | What Small molecule therapies have been approved by the FDA to treat mansonelliasis? | There are no drug Small molecule therapies approved to treat mansonelliasis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mansonelliasis" OR LOWER(mesh_heading) = "mansonelliasis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.365 | Q16 | What Small molecule therapies have been approved by the FDA to treat Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive? | There are no drug Small molecule therapies approved to treat Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "blast phase chronic myelogenous leukemia, bcr-abl1 positive" OR LOWER(mesh_heading) = "blast phase chronic myelogenous leukemia, bcr-abl1 positive") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1536 | Q16 | What Small molecule therapies have been approved by the FDA to treat prolymphocytic leukemia? | There are no drug Small molecule therapies approved to treat prolymphocytic leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "prolymphocytic leukemia" OR LOWER(mesh_heading) = "prolymphocytic leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.626 | Q16 | What Small molecule therapies have been approved by the FDA to treat Skin ulcer? | There are no drug Small molecule therapies approved to treat Skin ulcer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "skin ulcer" OR LOWER(mesh_heading) = "skin ulcer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.3 | Q16 | What Oligonucleotide therapies have been approved by the FDA to treat Hypercholesterolemia? | There are no drug Oligonucleotide therapies approved to treat Hypercholesterolemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypercholesterolemia" OR LOWER(mesh_heading) = "hypercholesterolemia") AND LOWER(drugType) = "oligonucleotide" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.7 | Q16 | What Oligonucleotide therapies have been approved by the FDA to treat familial amyloid neuropathy? | There are 3 Oligonucleotide therapy drugs that are approved to treat familial amyloid neuropathy which are as follows: Inotersen Sodium, Vutrisiran, and Patisiran Sodium. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "familial amyloid neuropathy" OR LOWER(mesh_heading) = "familial amyloid neuropathy") AND LOWER(drugType) = "oligonucleotide" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097642', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097645', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097648', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097651', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097654', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097657', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097660', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097662', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097664', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097666', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097668', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097670', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097672', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097674', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097676', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097678', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097680', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097682', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097684', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097687', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097690', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097693', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097696', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097699', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097702', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097705', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097708', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097711', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097714', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097717', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097720', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097723', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097726', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097729', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.313 | Q16 | What Protein therapies have been approved by the FDA to treat unspecified peripheral T-cell lymphoma? | There are no drug Protein therapies approved to treat unspecified peripheral T-cell lymphoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "unspecified peripheral t-cell lymphoma" OR LOWER(mesh_heading) = "unspecified peripheral t-cell lymphoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1188 | Q16 | What Small molecule therapies have been approved by the FDA to treat inborn errors of immunity? | Megestrol Acetate is the only Small molecule therapy approved by the FDA to treat inborn errors of immunity. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "inborn errors of immunity" OR LOWER(mesh_heading) = "inborn errors of immunity") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_940516', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Immunodeficiency Diseases', 'efo_term': 'inborn errors of immunity'}, {'UUID': 'DrugTargetsIndication121923_text_940537', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Immunodeficiency Diseases', 'efo_term': 'inborn errors of immunity'}, {'UUID': 'DrugTargetsIndication121923_text_940558', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Immunodeficiency Diseases', 'efo_term': 'inborn errors of immunity'}, {'UUID': 'DrugTargetsIndication121923_text_940579', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Immunodeficiency Diseases', 'efo_term': 'inborn errors of immunity'}, {'UUID': 'DrugTargetsIndication121923_text_940600', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Immunodeficiency Diseases', 'efo_term': 'inborn errors of immunity'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1532 | Q16 | What Small molecule therapies have been approved by the FDA to treat proctitis? | Mesalamine is the only Small molecule therapy approved by the FDA to treat proctitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "proctitis" OR LOWER(mesh_heading) = "proctitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_842630', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}, {'UUID': 'DrugTargetsIndication121923_text_842647', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}, {'UUID': 'DrugTargetsIndication121923_text_842664', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}, {'UUID': 'DrugTargetsIndication121923_text_842681', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}, {'UUID': 'DrugTargetsIndication121923_text_842698', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}, {'UUID': 'DrugTargetsIndication121923_text_842715', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}, {'UUID': 'DrugTargetsIndication121923_text_842732', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}, {'UUID': 'DrugTargetsIndication121923_text_842749', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}, {'UUID': 'DrugTargetsIndication121923_text_842766', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000132170', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}, {'UUID': 'DrugTargetsIndication121923_text_842783', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000132170', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}, {'UUID': 'DrugTargetsIndication121923_text_842800', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000132170', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}, {'UUID': 'DrugTargetsIndication121923_text_842817', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000132170', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}, {'UUID': 'DrugTargetsIndication121923_text_842834', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000012779', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}, {'UUID': 'DrugTargetsIndication121923_text_842851', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000012779', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}, {'UUID': 'DrugTargetsIndication121923_text_842868', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000012779', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}, {'UUID': 'DrugTargetsIndication121923_text_842885', 'drugName': 'Mesalamine', 'tradeNames_list': "['Apriso', 'Asacol', 'Asacol hd', 'Canasa', 'Coltec ec', 'Delzicol', 'IpocolLialda', 'Mesalamine', 'Mesren mr', 'Mezavant xl', 'Octasa', 'PentasaPentasa sr', 'Rowasa', 'Salofalk', 'Sfrowasa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000012779', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Proctitis', 'efo_term': 'proctitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.669 | Q16 | What Small molecule therapies have been approved by the FDA to treat Umbilical hernia? | There are no drug Small molecule therapies approved to treat Umbilical hernia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "umbilical hernia" OR LOWER(mesh_heading) = "umbilical hernia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.367 | Q16 | What Small molecule therapies have been approved by the FDA to treat Borderline personality disorder? | There are no drug Small molecule therapies approved to treat Borderline personality disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "borderline personality disorder" OR LOWER(mesh_heading) = "borderline personality disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1736 | Q16 | What Small molecule therapies have been approved by the FDA to treat uterine cervix carcinoma in situ? | There are no drug Small molecule therapies approved to treat uterine cervix carcinoma in situ. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "uterine cervix carcinoma in situ" OR LOWER(mesh_heading) = "uterine cervix carcinoma in situ") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.217 | Q16 | What Protein therapies have been approved by the FDA to treat menopause? | There are no drug Protein therapies approved to treat menopause. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "menopause" OR LOWER(mesh_heading) = "menopause") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.923 | Q16 | What Small molecule therapies have been approved by the FDA to treat chronic primary adrenal insufficiency? | There are no drug Small molecule therapies approved to treat chronic primary adrenal insufficiency. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic primary adrenal insufficiency" OR LOWER(mesh_heading) = "chronic primary adrenal insufficiency") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.28 | Q16 | What Protein therapies have been approved by the FDA to treat Beta-thalassemia? | There are no drug Protein therapies approved to treat Beta-thalassemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "beta-thalassemia" OR LOWER(mesh_heading) = "beta-thalassemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1259 | Q16 | What Small molecule therapies have been approved by the FDA to treat loiasis? | There are no drug Small molecule therapies approved to treat loiasis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "loiasis" OR LOWER(mesh_heading) = "loiasis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.529 | Q16 | What Small molecule therapies have been approved by the FDA to treat Laryngomalacia? | There are no drug Small molecule therapies approved to treat Laryngomalacia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "laryngomalacia" OR LOWER(mesh_heading) = "laryngomalacia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1613 | Q16 | What Small molecule therapies have been approved by the FDA to treat sensorineural hearing loss? | There are no drug Small molecule therapies approved to treat sensorineural hearing loss. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "sensorineural hearing loss" OR LOWER(mesh_heading) = "sensorineural hearing loss") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.913 | Q16 | What Small molecule therapies have been approved by the FDA to treat chronic hepatitis C virus infection? | There are 2 Small molecule therapy drugs that are approved to treat chronic hepatitis C virus infection which are as follows: Ribavirin and Eltrombopag Olamine. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic hepatitis c virus infection" OR LOWER(mesh_heading) = "chronic hepatitis c virus infection") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937566', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106348', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_937591', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106348', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1055948', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1055953', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1055958', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1055963', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1055968', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1055973', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1055978', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1055983', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1055988', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1055993', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1055998', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056003', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056008', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056013', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056018', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056023', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056028', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056033', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056038', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056043', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056048', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056053', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056058', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056063', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056068', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056073', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056078', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056083', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056088', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056093', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056098', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056103', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056108', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056113', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056118', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056123', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056128', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056133', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056138', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056143', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056148', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056153', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056158', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056163', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056168', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056173', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056178', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056183', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056188', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056193', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056198', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056203', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056208', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056213', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056218', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056223', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056228', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056233', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056238', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056243', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056248', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056253', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056258', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056263', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056268', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056273', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056278', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056283', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056288', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056293', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056298', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056303', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056308', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056313', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056318', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056323', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056328', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056333', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056338', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056343', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056348', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056353', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056358', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056363', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056368', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056373', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056378', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056383', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056388', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056393', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056398', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056403', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056408', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056413', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056418', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056423', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056428', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}, {'UUID': 'DrugTargetsIndication121923_text_1056433', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.642 | Q16 | What Small molecule therapies have been approved by the FDA to treat T-Cell Prolymphocytic Leukemia? | There are no drug Small molecule therapies approved to treat T-Cell Prolymphocytic Leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "t-cell prolymphocytic leukemia" OR LOWER(mesh_heading) = "t-cell prolymphocytic leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1017 | Q16 | What Small molecule therapies have been approved by the FDA to treat endocrine neoplasm? | There are no drug Small molecule therapies approved to treat endocrine neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "endocrine neoplasm" OR LOWER(mesh_heading) = "endocrine neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.724 | Q16 | What Small molecule therapies have been approved by the FDA to treat age-related macular degeneration? | There are no drug Small molecule therapies approved to treat age-related macular degeneration. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "age-related macular degeneration" OR LOWER(mesh_heading) = "age-related macular degeneration") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.696 | Q16 | What Small molecule therapies have been approved by the FDA to treat actinic keratosis? | There are 4 Small molecule therapy drugs that are approved to treat actinic keratosis which are as follows: Tirbanibulin, Diclofenac, Fluorouracil, and Imiquimod. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "actinic keratosis" OR LOWER(mesh_heading) = "actinic keratosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752054', 'drugName': 'Tirbanibulin', 'tradeNames_list': "['Klisyri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_752058', 'drugName': 'Tirbanibulin', 'tradeNames_list': "['Klisyri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_752062', 'drugName': 'Tirbanibulin', 'tradeNames_list': "['Klisyri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_752066', 'drugName': 'Tirbanibulin', 'tradeNames_list': "['Klisyri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_752070', 'drugName': 'Tirbanibulin', 'tradeNames_list': "['Klisyri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_752074', 'drugName': 'Tirbanibulin', 'tradeNames_list': "['Klisyri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_752078', 'drugName': 'Tirbanibulin', 'tradeNames_list': "['Klisyri']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_836978', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837008', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837038', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837068', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837098', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837128', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837158', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837188', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837218', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837248', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837278', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837308', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837338', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837368', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837398', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837428', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837458', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837488', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837518', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837548', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837578', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837608', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837638', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837668', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837698', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837728', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837758', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837788', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837818', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837848', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837878', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837908', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837938', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837968', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_837998', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_838028', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919465', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919514', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919567', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919620', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919673', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919726', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919779', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919832', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919885', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919938', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_919991', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_920044', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_920097', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_920150', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_920203', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_920256', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}, {'UUID': 'DrugTargetsIndication121923_text_920309', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000196664', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1381 | Q16 | What Small molecule therapies have been approved by the FDA to treat neuropathy? | There are no drug Small molecule therapies approved to treat neuropathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neuropathy" OR LOWER(mesh_heading) = "neuropathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1194 | Q16 | What Small molecule therapies have been approved by the FDA to treat inflammation? | There are 9 Small molecule therapy drugs that are approved to treat inflammation which are as follows: Loteprednol Etabonate, Dexamethasone, Hydrocortisone, Prednisolone Acetate, Lidocaine, Nepafenac, Diclofenac, Ketorolac Tromethamine, and Bromfenac Sodium. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "inflammation" OR LOWER(mesh_heading) = "inflammation") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_225413', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225421', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225429', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225437', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225445', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225453', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225461', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225469', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225477', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225485', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225493', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225501', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225509', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225517', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225525', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225533', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225541', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225549', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225557', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225565', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225573', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225581', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225589', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225597', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_225605', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_226319', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_226604', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_226889', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_227174', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_227459', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_227744', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_228029', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_228314', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_228599', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_228884', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_229169', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_229454', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_229739', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_230024', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_230309', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_230594', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_230879', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_231164', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_231449', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_231734', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_232019', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_232304', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_240810', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_240892', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_240974', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_241056', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_241138', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_241220', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_241302', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_241384', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_241466', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_241548', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_241630', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_241712', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_241794', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_241876', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_243743', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_243760', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_243777', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_243794', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_637780', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_637895', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_638010', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_638125', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_638240', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_638355', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_638470', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_638585', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_638700', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_638815', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_638930', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_639045', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_639160', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_639275', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_639390', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_639505', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_639620', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_639735', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_639850', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_639965', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_640080', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_640195', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_640310', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_640425', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_640540', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_640655', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_640770', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_640885', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_641000', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_641115', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_641230', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_641345', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_641460', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_641575', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_641690', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.628 | Q16 | What Small molecule therapies have been approved by the FDA to treat Smith-Lemli-Opitz syndrome? | There are no drug Small molecule therapies approved to treat Smith-Lemli-Opitz syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "smith-lemli-opitz syndrome" OR LOWER(mesh_heading) = "smith-lemli-opitz syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.8 | Q16 | What Oligonucleotide therapies have been approved by the FDA to treat familial hypercholesterolemia? | There are 2 Oligonucleotide therapy drugs that are approved to treat familial hypercholesterolemia which are as follows: Inclisiran Sodium and Mipomersen Sodium. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "familial hypercholesterolemia" OR LOWER(mesh_heading) = "familial hypercholesterolemia") AND LOWER(drugType) = "oligonucleotide" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993740', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993742', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993744', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993746', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993748', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993750', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993752', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993754', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993756', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993758', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993760', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993762', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993764', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993766', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993768', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993770', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993772', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993774', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_993776', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000169174', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1191789', 'drugName': 'Mipomersen Sodium', 'tradeNames_list': "['Kynamro']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000084674', 'approvedSymbol': 'APOB', 'approvedName': 'apolipoprotein B', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1191792', 'drugName': 'Mipomersen Sodium', 'tradeNames_list': "['Kynamro']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000084674', 'approvedSymbol': 'APOB', 'approvedName': 'apolipoprotein B', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}, {'UUID': 'DrugTargetsIndication121923_text_1191795', 'drugName': 'Mipomersen Sodium', 'tradeNames_list': "['Kynamro']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000084674', 'approvedSymbol': 'APOB', 'approvedName': 'apolipoprotein B', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.258 | Q16 | What Protein therapies have been approved by the FDA to treat plasma cell leukemia? | There are no drug Protein therapies approved to treat plasma cell leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "plasma cell leukemia" OR LOWER(mesh_heading) = "plasma cell leukemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.811 | Q16 | What Small molecule therapies have been approved by the FDA to treat bacterial vaginosis? | There are no drug Small molecule therapies approved to treat bacterial vaginosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bacterial vaginosis" OR LOWER(mesh_heading) = "bacterial vaginosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.26 | Q16 | What Protein therapies have been approved by the FDA to treat Back pain? | There are no drug Protein therapies approved to treat Back pain. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "back pain" OR LOWER(mesh_heading) = "back pain") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.338 | Q16 | What Small molecule therapies have been approved by the FDA to treat Anemia, Hemolytic, Autoimmune? | There are no drug Small molecule therapies approved to treat Anemia, Hemolytic, Autoimmune. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "anemia, hemolytic, autoimmune" OR LOWER(mesh_heading) = "anemia, hemolytic, autoimmune") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.576 | Q16 | What Small molecule therapies have been approved by the FDA to treat Oral leukoplakia? | There are no drug Small molecule therapies approved to treat Oral leukoplakia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "oral leukoplakia" OR LOWER(mesh_heading) = "oral leukoplakia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.48 | Q16 | What Protein therapies have been approved by the FDA to treat Ischemic stroke? | There are no drug Protein therapies approved to treat Ischemic stroke. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ischemic stroke" OR LOWER(mesh_heading) = "ischemic stroke") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1298 | Q16 | What Small molecule therapies have been approved by the FDA to treat medullary thyroid gland carcinoma? | There are 3 Small molecule therapy drugs that are approved to treat medullary thyroid gland carcinoma which are as follows: Vandetanib, Pralsetinib, and Selpercatinib. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "medullary thyroid gland carcinoma" OR LOWER(mesh_heading) = "medullary thyroid gland carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_209949', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_209997', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210045', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210093', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210141', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210189', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210237', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210285', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210333', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210381', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210429', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210477', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210525', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210573', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210621', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210669', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210717', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210765', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210813', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210861', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210909', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_210957', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211005', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211053', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211101', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211149', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211197', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211245', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211293', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211341', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211389', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211437', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211485', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211533', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211581', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211629', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211677', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211725', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211773', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211821', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211869', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211917', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_211965', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212013', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212061', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212109', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212157', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212205', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212253', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212301', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212349', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212397', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212445', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212493', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212541', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212589', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212637', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212685', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212733', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212781', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212829', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212877', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212925', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_212973', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213021', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213069', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213117', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213165', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213213', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213261', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213309', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213357', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213405', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213453', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213501', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213549', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213597', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213645', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213693', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213741', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213789', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213837', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213885', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213933', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_213981', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214029', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214077', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214125', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214173', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214221', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214269', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214317', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214365', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214413', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214461', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214509', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214557', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214605', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214653', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_214701', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.107 | Q16 | What Protein therapies have been approved by the FDA to treat brain injury? | There are no drug Protein therapies approved to treat brain injury. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "brain injury" OR LOWER(mesh_heading) = "brain injury") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.352 | Q16 | What Small molecule therapies have been approved by the FDA to treat Autoimmune Hepatitis? | There are no drug Small molecule therapies approved to treat Autoimmune Hepatitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "autoimmune hepatitis" OR LOWER(mesh_heading) = "autoimmune hepatitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.56 | Q16 | What Protein therapies have been approved by the FDA to treat Parkinson disease? | There are no drug Protein therapies approved to treat Parkinson disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "parkinson disease" OR LOWER(mesh_heading) = "parkinson disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.240 | Q16 | What Protein therapies have been approved by the FDA to treat non-Hodgkins lymphoma? | There are no drug Protein therapies approved to treat non-Hodgkins lymphoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "non-hodgkins lymphoma" OR LOWER(mesh_heading) = "non-hodgkins lymphoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.215 | Q16 | What Protein therapies have been approved by the FDA to treat membranous glomerulonephritis? | There are no drug Protein therapies approved to treat membranous glomerulonephritis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "membranous glomerulonephritis" OR LOWER(mesh_heading) = "membranous glomerulonephritis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.121 | Q16 | What Protein therapies have been approved by the FDA to treat central precocious puberty? | Leuprolide Acetate is the only Protein therapy approved by the FDA to treat central precocious puberty. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "central precocious puberty" OR LOWER(mesh_heading) = "central precocious puberty") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097005', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097008', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097027', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097030', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097049', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097052', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097071', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097074', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097093', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097096', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097115', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097118', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097287', 'drugName': 'Triptorelin Pamoate', 'tradeNames_list': "['Trelstar', 'Triptodur kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}, {'UUID': 'DrugTargetsIndication121923_text_1097294', 'drugName': 'Triptorelin Pamoate', 'tradeNames_list': "['Trelstar', 'Triptodur kit']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Puberty, Precocious', 'efo_term': 'Central precocious puberty'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1110 | Q16 | What Small molecule therapies have been approved by the FDA to treat glioblastoma multiforme? | There are no drug Small molecule therapies approved to treat glioblastoma multiforme. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "glioblastoma multiforme" OR LOWER(mesh_heading) = "glioblastoma multiforme") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.993 | Q16 | What Small molecule therapies have been approved by the FDA to treat differentiated thyroid carcinoma? | Levothyroxine Sodium is the only Small molecule therapy approved by the FDA to treat differentiated thyroid carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "differentiated thyroid carcinoma" OR LOWER(mesh_heading) = "differentiated thyroid carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924800', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924807', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924814', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924821', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924828', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924835', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924842', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924849', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924856', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924863', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924870', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924877', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924884', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924891', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924898', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924905', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924912', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924919', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924926', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924933', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924940', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924947', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924954', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924961', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924968', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924975', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924982', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924989', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_924996', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925003', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925010', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925017', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925024', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925031', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925038', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925045', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925052', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925059', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925066', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925073', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925080', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925087', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925094', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925101', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925108', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925115', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925122', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925129', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925136', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925143', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925150', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925157', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925164', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925171', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925178', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925185', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925192', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925199', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925206', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925213', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925220', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925227', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925234', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925241', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925248', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925255', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925262', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925269', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925276', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925283', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925290', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925297', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925304', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925311', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925318', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925325', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925332', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925339', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925346', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925353', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925360', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925367', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925374', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925381', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925388', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925395', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925402', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925409', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925416', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925423', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925430', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925437', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925444', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925451', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925458', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925465', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925472', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925479', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925486', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_925493', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.801 | Q16 | What Small molecule therapies have been approved by the FDA to treat autism? | There are 3 Small molecule therapy drugs that are approved to treat autism which are as follows: Risperidone, Aripiprazole Lauroxil, and Aripiprazole. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "autism" OR LOWER(mesh_heading) = "autism") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_149489', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_149522', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_149555', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_149588', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_149621', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_149654', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_149687', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_149720', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_149753', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_149786', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_149819', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_149852', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_149885', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_149918', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_149951', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_149984', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150017', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150050', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150083', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150116', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150149', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150182', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150215', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150248', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150281', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150314', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150347', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150380', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150413', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150446', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150479', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150512', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150545', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150578', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150611', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150644', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150677', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150710', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150743', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150776', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150809', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150842', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150875', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150908', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150941', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_150974', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_151007', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_151040', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_151073', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_151106', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_151139', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_151172', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_151205', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_151238', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_157997', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158003', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158009', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158015', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158021', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158027', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158033', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158039', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158045', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158051', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158057', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158063', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158069', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158075', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158081', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158087', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158093', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158099', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158105', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158111', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158117', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158123', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158129', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158135', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158141', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158147', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158153', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158159', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158165', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158171', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158177', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158183', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158189', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158195', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158201', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158207', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158213', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158219', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158225', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158231', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158237', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158243', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158249', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158255', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158261', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}, {'UUID': 'DrugTargetsIndication121923_text_158267', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.73 | Q16 | What Protein therapies have been approved by the FDA to treat Weight loss? | There are no drug Protein therapies approved to treat Weight loss. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "weight loss" OR LOWER(mesh_heading) = "weight loss") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.820 | Q16 | What Small molecule therapies have been approved by the FDA to treat biliary liver cirrhosis? | Obeticholic Acid is the only Small molecule therapy approved by the FDA to treat biliary liver cirrhosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "biliary liver cirrhosis" OR LOWER(mesh_heading) = "biliary liver cirrhosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1104322', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104337', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104352', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104367', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104382', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104397', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104412', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104427', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104442', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104457', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104472', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104487', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104502', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104517', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104532', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104547', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104562', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104577', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104592', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}, {'UUID': 'DrugTargetsIndication121923_text_1104607', 'drugName': 'Obeticholic Acid', 'tradeNames_list': "['Ocaliva']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Cirrhosis, Biliary', 'efo_term': 'biliary liver cirrhosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1520 | Q16 | What Small molecule therapies have been approved by the FDA to treat primary adrenal insufficiency? | There are 2 Small molecule therapy drugs that are approved to treat primary adrenal insufficiency which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "primary adrenal insufficiency" OR LOWER(mesh_heading) = "primary adrenal insufficiency") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217682', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_217890', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_218098', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_218306', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_218514', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_218722', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_218930', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_219138', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_219346', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_219554', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_219762', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_219970', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_220178', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_220386', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_220594', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_220802', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_226383', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_226668', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_226953', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_227238', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_227523', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_227808', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_228093', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_228378', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_228663', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_228948', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_229233', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_229518', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_229803', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_230088', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_230373', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_230658', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_230943', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_231228', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_231513', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_231798', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_232083', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_232368', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.78 | Q16 | What Protein therapies have been approved by the FDA to treat acute coronary syndrome? | There are no drug Protein therapies approved to treat acute coronary syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute coronary syndrome" OR LOWER(mesh_heading) = "acute coronary syndrome") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.973 | Q16 | What Small molecule therapies have been approved by the FDA to treat deafness? | There are no drug Small molecule therapies approved to treat deafness. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "deafness" OR LOWER(mesh_heading) = "deafness") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.46 | Q16 | What Protein therapies have been approved by the FDA to treat Hypocalcemia? | There are no drug Protein therapies approved to treat Hypocalcemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypocalcemia" OR LOWER(mesh_heading) = "hypocalcemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1476 | Q16 | What Small molecule therapies have been approved by the FDA to treat phobic disorder? | There are no drug Small molecule therapies approved to treat phobic disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "phobic disorder" OR LOWER(mesh_heading) = "phobic disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.527 | Q16 | What Small molecule therapies have been approved by the FDA to treat Landau-Kleffner syndrome? | There are no drug Small molecule therapies approved to treat Landau-Kleffner syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "landau-kleffner syndrome" OR LOWER(mesh_heading) = "landau-kleffner syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.234 | Q16 | What Protein therapies have been approved by the FDA to treat neuroblastoma? | There are no drug Protein therapies approved to treat neuroblastoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neuroblastoma" OR LOWER(mesh_heading) = "neuroblastoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.648 | Q16 | What Small molecule therapies have been approved by the FDA to treat Tachycardia? | There are no drug Small molecule therapies approved to treat Tachycardia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "tachycardia" OR LOWER(mesh_heading) = "tachycardia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1377 | Q16 | What Small molecule therapies have been approved by the FDA to treat neurofibromatosis type 2? | There are no drug Small molecule therapies approved to treat neurofibromatosis type 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neurofibromatosis type 2" OR LOWER(mesh_heading) = "neurofibromatosis type 2") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1327 | Q16 | What Small molecule therapies have been approved by the FDA to treat mixed neoplasm? | There are no drug Small molecule therapies approved to treat mixed neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mixed neoplasm" OR LOWER(mesh_heading) = "mixed neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1058 | Q16 | What Small molecule therapies have been approved by the FDA to treat familial amyloid neuropathy? | There are no drug Small molecule therapies approved to treat familial amyloid neuropathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "familial amyloid neuropathy" OR LOWER(mesh_heading) = "familial amyloid neuropathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.537 | Q16 | What Small molecule therapies have been approved by the FDA to treat Lynch syndrome? | There are no drug Small molecule therapies approved to treat Lynch syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lynch syndrome" OR LOWER(mesh_heading) = "lynch syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1130 | Q16 | What Small molecule therapies have been approved by the FDA to treat hemangioma? | There are no drug Small molecule therapies approved to treat hemangioma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hemangioma" OR LOWER(mesh_heading) = "hemangioma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1328 | Q16 | What Small molecule therapies have been approved by the FDA to treat monoclonal gammopathy? | There are no drug Small molecule therapies approved to treat monoclonal gammopathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "monoclonal gammopathy" OR LOWER(mesh_heading) = "monoclonal gammopathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.607 | Q16 | What Small molecule therapies have been approved by the FDA to treat Radiation-induced nausea and vomiting? | Ondansetron is the only Small molecule therapy approved by the FDA to treat Radiation-induced nausea and vomiting. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "radiation-induced nausea and vomiting" OR LOWER(mesh_heading) = "radiation-induced nausea and vomiting") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205863', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205903', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205943', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting'}, {'UUID': 'DrugTargetsIndication121923_text_205983', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.469 | Q16 | What Small molecule therapies have been approved by the FDA to treat HIV-associated nephropathy? | There are no drug Small molecule therapies approved to treat HIV-associated nephropathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hiv-associated nephropathy" OR LOWER(mesh_heading) = "hiv-associated nephropathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1416 | Q16 | What Small molecule therapies have been approved by the FDA to treat orthostatic intolerance? | There are no drug Small molecule therapies approved to treat orthostatic intolerance. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "orthostatic intolerance" OR LOWER(mesh_heading) = "orthostatic intolerance") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.796 | Q16 | What Small molecule therapies have been approved by the FDA to treat atrial fibrillation? | There are 5 Small molecule therapy drugs that are approved to treat atrial fibrillation which are as follows: Dronedarone Hydrochloride, Rivaroxaban, Edoxaban Tosylate, Apixaban, and Dabigatran Etexilate Mesylate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "atrial fibrillation" OR LOWER(mesh_heading) = "atrial fibrillation") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_457117', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457118', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457119', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457120', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457121', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457122', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457123', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457124', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457125', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457126', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457127', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457128', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457129', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457130', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457131', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457132', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457133', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457134', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457135', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457136', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457137', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457138', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457139', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457140', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457141', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457142', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457143', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457144', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457145', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457146', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457147', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457148', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457149', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457150', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457151', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457152', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457153', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457154', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457155', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457156', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457157', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457158', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457159', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457160', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457161', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457162', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457163', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457164', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457165', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457166', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457167', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457168', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457169', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457170', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457171', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457172', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457173', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457174', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457175', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457176', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457177', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457178', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457179', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457180', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457181', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457182', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457183', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457184', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457185', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457186', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457187', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000138622', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457188', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000138622', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457189', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000138622', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457190', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000138622', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457191', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000138622', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457192', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000123700', 'approvedSymbol': 'KCNJ2', 'approvedName': 'potassium inwardly rectifying channel subfamily J member 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457193', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000123700', 'approvedSymbol': 'KCNJ2', 'approvedName': 'potassium inwardly rectifying channel subfamily J member 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457194', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000123700', 'approvedSymbol': 'KCNJ2', 'approvedName': 'potassium inwardly rectifying channel subfamily J member 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457195', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000123700', 'approvedSymbol': 'KCNJ2', 'approvedName': 'potassium inwardly rectifying channel subfamily J member 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_457196', 'drugName': 'Dronedarone Hydrochloride', 'tradeNames_list': "['Multaq']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000123700', 'approvedSymbol': 'KCNJ2', 'approvedName': 'potassium inwardly rectifying channel subfamily J member 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_708681', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_708716', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_708751', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_708786', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_708821', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_708856', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_708891', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_708926', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_708961', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_708996', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_709031', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_709066', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_709101', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_709136', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_709171', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_709206', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_709241', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_709276', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_709311', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}, {'UUID': 'DrugTargetsIndication121923_text_709346', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1493 | Q16 | What Small molecule therapies have been approved by the FDA to treat polycystic ovary syndrome? | There are no drug Small molecule therapies approved to treat polycystic ovary syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "polycystic ovary syndrome" OR LOWER(mesh_heading) = "polycystic ovary syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1045 | Q16 | What Small molecule therapies have been approved by the FDA to treat essential tremor? | There are no drug Small molecule therapies approved to treat essential tremor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "essential tremor" OR LOWER(mesh_heading) = "essential tremor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1149 | Q16 | What Small molecule therapies have been approved by the FDA to treat hidradenitis suppurativa? | There are no drug Small molecule therapies approved to treat hidradenitis suppurativa. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hidradenitis suppurativa" OR LOWER(mesh_heading) = "hidradenitis suppurativa") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.61 | Q16 | What Protein therapies have been approved by the FDA to treat Renal insufficiency? | There are no drug Protein therapies approved to treat Renal insufficiency. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "renal insufficiency" OR LOWER(mesh_heading) = "renal insufficiency") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1117 | Q16 | What Small molecule therapies have been approved by the FDA to treat graft versus host disease? | Belumosudil Mesylate is the only Small molecule therapy approved by the FDA to treat graft versus host disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "graft versus host disease" OR LOWER(mesh_heading) = "graft versus host disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1076376', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease'}, {'UUID': 'DrugTargetsIndication121923_text_1076377', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease'}, {'UUID': 'DrugTargetsIndication121923_text_1076378', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease'}, {'UUID': 'DrugTargetsIndication121923_text_1076379', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease'}, {'UUID': 'DrugTargetsIndication121923_text_1076380', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134318', 'approvedSymbol': 'ROCK2', 'approvedName': 'Rho associated coiled-coil containing protein kinase 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease'}, {'UUID': 'DrugTargetsIndication121923_text_1076381', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067900', 'approvedSymbol': 'ROCK1', 'approvedName': 'Rho associated coiled-coil containing protein kinase 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease'}, {'UUID': 'DrugTargetsIndication121923_text_1076382', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067900', 'approvedSymbol': 'ROCK1', 'approvedName': 'Rho associated coiled-coil containing protein kinase 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease'}, {'UUID': 'DrugTargetsIndication121923_text_1076383', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067900', 'approvedSymbol': 'ROCK1', 'approvedName': 'Rho associated coiled-coil containing protein kinase 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease'}, {'UUID': 'DrugTargetsIndication121923_text_1076384', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067900', 'approvedSymbol': 'ROCK1', 'approvedName': 'Rho associated coiled-coil containing protein kinase 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease'}, {'UUID': 'DrugTargetsIndication121923_text_1076385', 'drugName': 'Belumosudil Mesylate', 'tradeNames_list': "['Rezurock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067900', 'approvedSymbol': 'ROCK1', 'approvedName': 'Rho associated coiled-coil containing protein kinase 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Graft vs Host Disease', 'efo_term': 'graft versus host disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.93 | Q16 | What Protein therapies have been approved by the FDA to treat anterior uveitis? | There are no drug Protein therapies approved to treat anterior uveitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "anterior uveitis" OR LOWER(mesh_heading) = "anterior uveitis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.670 | Q16 | What Small molecule therapies have been approved by the FDA to treat Unverricht-Lundborg disease? | There are no drug Small molecule therapies approved to treat Unverricht-Lundborg disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "unverricht-lundborg disease" OR LOWER(mesh_heading) = "unverricht-lundborg disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.949 | Q16 | What Small molecule therapies have been approved by the FDA to treat complex regional pain syndrome? | There are no drug Small molecule therapies approved to treat complex regional pain syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "complex regional pain syndrome" OR LOWER(mesh_heading) = "complex regional pain syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1489 | Q16 | What Small molecule therapies have been approved by the FDA to treat pneumonia? | There are 4 Small molecule therapy drugs that are approved to treat pneumonia which are as follows: Prednisone, Dexamethasone, Hydrocortisone, and Doxycycline. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pneumonia" OR LOWER(mesh_heading) = "pneumonia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217639', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_217847', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_218055', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_218263', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_218471', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_218679', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_218887', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_219095', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_219303', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_219511', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_219719', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_219927', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_220135', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_220343', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_220551', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_220759', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_226332', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_226617', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_226902', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_227187', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_227472', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_227757', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_228042', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_228327', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_228612', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_228897', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_229182', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_229467', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_229752', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_230037', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_230322', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_230607', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_230892', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_231177', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_231462', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_231747', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_232032', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_232317', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_240814', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_240896', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_240978', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_241060', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_241142', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_241224', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_241306', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_241388', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_241470', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_241552', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_241634', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_241716', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_241798', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_241880', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1037846', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1037921', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1037996', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1038071', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1038146', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1038221', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1038296', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1038371', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1038446', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1038521', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1038596', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1038671', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1038746', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1038821', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1038896', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1038971', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1039046', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1039121', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1039196', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1039271', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1039346', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1039421', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1039496', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1039571', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1039646', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1039721', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1039796', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1039871', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1039946', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1040021', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1040096', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1040171', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1040246', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1040321', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1040396', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1040471', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1040546', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1040621', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1040696', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1040771', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1040846', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1040921', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1040996', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}, {'UUID': 'DrugTargetsIndication121923_text_1041071', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.195 | Q16 | What Protein therapies have been approved by the FDA to treat kidney cancer? | There are no drug Protein therapies approved to treat kidney cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "kidney cancer" OR LOWER(mesh_heading) = "kidney cancer") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.282 | Q16 | What Protein therapies have been approved by the FDA to treat renal cell carcinoma? | There are no drug Protein therapies approved to treat renal cell carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "renal cell carcinoma" OR LOWER(mesh_heading) = "renal cell carcinoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.700 | Q16 | What Small molecule therapies have been approved by the FDA to treat acute erythroleukemia? | There are no drug Small molecule therapies approved to treat acute erythroleukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute erythroleukemia" OR LOWER(mesh_heading) = "acute erythroleukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.